Global Non-Opioid Pain Drug Market Growth (Status and Outlook) 2026-2032
The global Non-Opioid Pain Drug market size is predicted to grow from US$ 41237 million in 2025 to US$ 56903 million in 2032; it is expected to grow at a CAGR of 4.7% from 2026 to 2032.
Non-Opioid Pain Drug refers to pharmaceutical products that provide analgesic effects without relying on opioid receptor agonism as their primary pain-relief mechanism. The market covers a broad therapeutic spectrum ranging from established systemic analgesics to newer mechanism-specific and site-directed therapies, with major product categories including acetaminophen/paracetamol, nonsteroidal anti-inflammatory drugs (NSAIDs), selective COX-2 inhibitors, sodium channel pain signal inhibitors, local anesthetic analgesics, capsaicin-based analgesics, anticonvulsant analgesics, antidepressant analgesics and other non-opioid therapies. Products are commercialized as single-agent or combination drugs, across prescription and over-the-counter channels, and in oral, injectable, topical, transdermal and other formulations. The principal clinical applications include postoperative pain, musculoskeletal pain, arthritis pain, neuropathic pain, headache and migraine, dental pain, back pain, menstrual pain, injury and trauma pain, and selected cancer-related pain settings. The research focus therefore spans both high-volume routine pain management and differentiated prescription therapies designed for more targeted, prolonged or opioid-sparing analgesia.
Key Findings
The average gross profit margin of this product is 45%
NSAIDs and acetaminophen remain the broadest treatment foundation across pain care
Prescription innovation increasingly targets peripheral pain signaling without opioid receptor activation
Postoperative pain is a strategic field for long acting local analgesia
Oral drugs anchor routine use while topical formats widen treatment access
Competition spans consumer health specialty pharma and broad generic portfolios
Market Trends
The Non-Opioid Pain Drug market is moving from a structure dominated primarily by conventional systemic analgesics toward a more diversified treatment model combining established drugs, mechanism-targeted therapies, localized delivery and multimodal pain management. NSAIDs and acetaminophen continue to underpin routine acute and musculoskeletal pain treatment, while innovation is increasingly focused on improving analgesic selectivity, duration of action and site specificity. The U.S. FDA approval of suzetrigine in 2025 introduced a new class of oral non-opioid analgesia targeting peripheral sodium-channel-mediated pain signaling, illustrating the industry's growing interest in treating pain before signals reach central pathways. At the same time, prolonged local anesthetic formulations and dual-mechanism perioperative therapies are broadening the role of non-opioid drugs in postoperative pain management. Consumer pain-care products are also evolving through differentiated release profiles, topical formulations and fixed-dose combinations. The long-term direction of the market is therefore shifting from simply replacing opioids with conventional analgesics toward matching different pain mechanisms, treatment durations and clinical scenarios with more specialized non-opioid options.
Market Dynamics
Drivers
Demand for Non-Opioid Pain Drug products is supported by the persistent clinical burden of acute and chronic pain and by efforts to minimize unnecessary opioid exposure where effective alternatives are available. Non-opioid therapies already play an established role in common acute pain conditions, including musculoskeletal injuries, back pain and minor procedural pain, while acetaminophen, oral and topical NSAIDs and other non-opioid medicines remain widely integrated into routine treatment pathways. Clinical practice is increasingly emphasizing treatment selection according to pain type, expected duration, patient risk factors and functional goals rather than relying on a single analgesic class. This creates a broad demand base covering both consumer self-care products and prescription therapies. Perioperative care represents an additional driver as hospitals and clinicians increasingly use multimodal analgesic strategies combining systemic medicines with long-acting or site-specific local therapies to improve pain control while reducing reliance on opioid rescue medication.
Restraints
The principal limitation of the Non-Opioid Pain Drug market is that non-opioid does not mean clinically unrestricted. Established drug classes have well-defined dosing, contraindication and tolerability considerations that limit their use in particular patient populations. NSAIDs, for example, are associated with gastrointestinal and cardiovascular risks that become particularly relevant in older patients, patients with underlying disease and prolonged treatment settings. Other therapeutic classes similarly require patient-specific assessment and may not provide adequate analgesia for every pain severity or mechanism. At the commercial level, many traditional non-opioid analgesics are mature and highly genericized, creating strong price competition and limiting differentiation for standard formulations. Conversely, newer proprietary therapies may face higher treatment costs, reimbursement scrutiny and formulary barriers. The market consequently operates between two pressures: commoditization in established drug classes and the need for newer therapies to demonstrate sufficient clinical and economic value to justify premium positioning.
Opportunities
The most important opportunity lies in expanding the therapeutic space between conventional first-line analgesics and opioid therapy. Mechanism-specific oral medicines, prolonged local anesthetics, topical and transdermal therapies and rational combination products provide multiple routes for companies to address this gap. Acute moderate-to-severe pain is becoming particularly important because successful non-opioid products can potentially participate in treatment settings historically associated with substantial opioid use. The emergence of peripheral sodium channel pain signal inhibition demonstrates the potential for fundamentally new analgesic mechanisms, while extended-duration local therapies create opportunities in surgery and procedure-related pain. Additional opportunities exist in neuropathic pain, musculoskeletal disorders and targeted topical treatment, where patient heterogeneity favors differentiated therapeutic approaches. Combination products also offer potential to improve onset, duration or multimodal efficacy without relying on opioid components, supporting continued product reformulation and lifecycle innovation across both prescription and consumer-health markets.
Challenges
A central challenge for the Non-Opioid Pain Drug industry is translating pharmacological innovation into clinically meaningful advantages across highly heterogeneous pain conditions. Pain intensity is subjective, treatment response differs substantially among patients, and acute, inflammatory, neuropathic and postoperative pain involve different biological mechanisms. A therapy that performs well in one setting therefore cannot automatically establish broad value across the entire pain market. New prescription products must demonstrate not only statistically significant pain reduction but also clinically relevant improvements in duration, tolerability, functional recovery, opioid-sparing potential or ease of use. Companies must then secure reimbursement, hospital formulary access, physician adoption and patient acceptance while competing against inexpensive generic analgesics. Long development timelines and demanding clinical endpoints further increase commercialization risk. As the number of non-opioid approaches expands, differentiation will increasingly depend on clearly identifying the pain population, treatment setting and clinical value proposition in which each therapy provides a meaningful advantage.
Industry Chain Analysis
The upstream portion of the Non-Opioid Pain Drug industry consists primarily of active pharmaceutical ingredients, pharmaceutical intermediates, excipients and specialized formulation or drug-delivery materials. Conventional oral analgesics rely heavily on mature API manufacturing and large-scale solid-dose production, making manufacturing efficiency, quality control and supply security important competitive factors. More differentiated products introduce additional technical requirements, including sustained-release technologies, liposomal delivery systems, transdermal matrices, topical penetration systems and specialized injectable formulations. These technologies increase formulation complexity and can shift value creation away from the active ingredient alone toward proprietary delivery platforms, manufacturing know-how and intellectual property.
The midstream encompasses formulation development, clinical development, regulatory approval, commercial manufacturing, brand management and lifecycle management. Downstream channels differ significantly by product positioning: over-the-counter analgesics depend heavily on pharmacies, retail and consumer-health distribution, while prescription products rely more strongly on hospitals, physicians, specialty pharmacy and institutional formularies. In postoperative applications, adoption is closely linked to surgical protocols and hospital pain-management pathways. The value chain is therefore bifurcated. Mature generic products derive competitive advantage from manufacturing scale, procurement efficiency and channel coverage, whereas innovative non-opioid therapies capture value through differentiated mechanisms, longer duration of action, targeted delivery, clinical evidence and intellectual-property protection.
Segment Insights
From a Type perspective, acetaminophen/paracetamol and NSAIDs represent the broadest foundation of the Non-Opioid Pain Drug market because of their established role across common acute, inflammatory, dental, musculoskeletal and self-treated pain. Selective COX-2 inhibitors occupy a more differentiated anti-inflammatory position, while local anesthetic analgesics have particular relevance in procedural and postoperative settings. Sodium channel pain signal inhibitors represent an emerging mechanism-oriented segment following the introduction of a first-in-class therapy for moderate-to-severe acute pain. Capsaicin-based products, anticonvulsant analgesics and antidepressant analgesics address more specialized pain mechanisms, particularly neuropathic and chronic pain conditions. The market is consequently becoming more segmented by pain biology rather than being defined only by analgesic strength.
Across Class, Group and Sort, single-agent drugs continue to provide the core treatment base, while combination products offer opportunities for complementary mechanisms and differentiated duration or onset of action. Prescription products are particularly important where pain severity, comorbidity or specialized delivery requires physician supervision, whereas OTC medicines remain central to everyday pain self-management. Oral formulations provide the widest routine-use platform, but injectable, topical and transdermal products allow treatment to become more site-specific and can address patients or clinical scenarios where systemic exposure is less desirable. The development of prolonged local analgesia and increasingly differentiated topical pain products suggests that formulation technology is becoming an important source of competitive separation alongside active pharmaceutical innovation.
Downstream Market Opportunities
Downstream demand for Non-Opioid Pain Drug products spans everyday self-treated pain and highly managed clinical pain pathways. Musculoskeletal pain, arthritis, back pain, headache and migraine, dental pain and menstrual pain provide recurring demand for accessible oral and topical products, while neuropathic pain requires more mechanism-specific pharmacotherapy. Postoperative pain represents one of the most strategically important opportunities because treatment decisions occur within structured hospital and surgical protocols where duration of analgesia, recovery quality and opioid-sparing potential can materially influence product selection. Injury and trauma pain also support short-term acute treatment demand, while selected cancer-related pain settings create opportunities for non-opioid medicines as components of multimodal therapy. The major commercial opportunity is therefore not a single application, but the progressive segmentation of pain management according to etiology, severity, duration and treatment setting.
Regional Insights
North America is an important innovation and commercialization market for Non-Opioid Pain Drug products, particularly for novel prescription mechanisms and perioperative pain-management therapies. Recent regulatory progress in peripheral sodium channel inhibition and continued development of extended-duration local analgesics demonstrate active efforts to broaden non-opioid treatment options in acute and postoperative pain. The region also has a mature consumer-health market supported by established OTC analgesic brands. Europe similarly represents a mature market, with significant use of both prescription and OTC pain medicines and opportunities centered on formulation differentiation, localized pain treatment and improved patient selection.
Asia-Pacific combines a large base of conventional analgesic use with expanding demand for branded OTC products, prescription pain management and differentiated formulations. Japan has a well-developed topical and transdermal pain-treatment tradition, while China combines large-scale generic pharmaceutical manufacturing with increasing development of innovative and higher-value prescription therapies. Across emerging markets, affordability and broad distribution remain critical, meaning established oral drugs are likely to retain substantial importance even as more specialized products expand. Regional competition will therefore remain structurally different: innovation and premium prescription therapies are more prominent in developed markets, while manufacturing economics, accessibility and channel penetration remain especially influential in price-sensitive markets.
Competitive Landscape Analysis
The competitive landscape is structurally diversified rather than dominated by one type of pharmaceutical company. Within the confirmed company set, Kenvue, Haleon and Bayer participate strongly through established consumer pain-care portfolios, while Vertex Pharmaceuticals Incorporated, Pfizer Inc., Pacira BioSciences, Inc., Heron Therapeutics, Inc., Scilex Holding Company and Gr?nenthal GmbH represent prescription or specialty-pharma approaches to differentiated pain management. Hisamitsu Pharmaceutical Co., Inc., Daiichi Sankyo Healthcare Co., Ltd. and AFT Pharmaceuticals Limited add regional and formulation-focused positions, while Viatris Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd. and Sun Pharmaceutical Industries Ltd. participate through broad pharmaceutical portfolios and large-scale manufacturing capabilities; Jiangsu Hengrui Pharmaceuticals Co., Ltd. represents the confirmed Chinese participant in the research scope. Competition therefore occurs across several dimensions simultaneously: consumer brand recognition, manufacturing scale, prescription access, formulation technology, proprietary mechanisms, clinical evidence and distribution reach. Recent progress in selective peripheral pain signaling and prolonged local analgesia indicates that future competitive differentiation is likely to rely increasingly on mechanism specificity and demonstrable clinical value rather than simple expansion of conventional analgesic portfolios.
Report Scope
LPI (LP Information)' newest research report, the “Non-Opioid Pain Drug Industry Forecast” looks at past sales and reviews total world Non-Opioid Pain Drug sales in 2025, providing a comprehensive analysis by region and market sector of projected Non-Opioid Pain Drug sales for 2026 through 2032. With Non-Opioid Pain Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Non-Opioid Pain Drug industry.
This Insight Report provides a comprehensive analysis of the global Non-Opioid Pain Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Non-Opioid Pain Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Non-Opioid Pain Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Non-Opioid Pain Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Non-Opioid Pain Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Non-Opioid Pain Drug market by product type, application, key players and key regions and countries.
Market Segmentation
Non-Opioid Pain Drug refers to pharmaceutical products that provide analgesic effects without relying on opioid receptor agonism as their primary pain-relief mechanism. The market covers a broad therapeutic spectrum ranging from established systemic analgesics to newer mechanism-specific and site-directed therapies, with major product categories including acetaminophen/paracetamol, nonsteroidal anti-inflammatory drugs (NSAIDs), selective COX-2 inhibitors, sodium channel pain signal inhibitors, local anesthetic analgesics, capsaicin-based analgesics, anticonvulsant analgesics, antidepressant analgesics and other non-opioid therapies. Products are commercialized as single-agent or combination drugs, across prescription and over-the-counter channels, and in oral, injectable, topical, transdermal and other formulations. The principal clinical applications include postoperative pain, musculoskeletal pain, arthritis pain, neuropathic pain, headache and migraine, dental pain, back pain, menstrual pain, injury and trauma pain, and selected cancer-related pain settings. The research focus therefore spans both high-volume routine pain management and differentiated prescription therapies designed for more targeted, prolonged or opioid-sparing analgesia.
Key Findings
The average gross profit margin of this product is 45%
NSAIDs and acetaminophen remain the broadest treatment foundation across pain care
Prescription innovation increasingly targets peripheral pain signaling without opioid receptor activation
Postoperative pain is a strategic field for long acting local analgesia
Oral drugs anchor routine use while topical formats widen treatment access
Competition spans consumer health specialty pharma and broad generic portfolios
Market Trends
The Non-Opioid Pain Drug market is moving from a structure dominated primarily by conventional systemic analgesics toward a more diversified treatment model combining established drugs, mechanism-targeted therapies, localized delivery and multimodal pain management. NSAIDs and acetaminophen continue to underpin routine acute and musculoskeletal pain treatment, while innovation is increasingly focused on improving analgesic selectivity, duration of action and site specificity. The U.S. FDA approval of suzetrigine in 2025 introduced a new class of oral non-opioid analgesia targeting peripheral sodium-channel-mediated pain signaling, illustrating the industry's growing interest in treating pain before signals reach central pathways. At the same time, prolonged local anesthetic formulations and dual-mechanism perioperative therapies are broadening the role of non-opioid drugs in postoperative pain management. Consumer pain-care products are also evolving through differentiated release profiles, topical formulations and fixed-dose combinations. The long-term direction of the market is therefore shifting from simply replacing opioids with conventional analgesics toward matching different pain mechanisms, treatment durations and clinical scenarios with more specialized non-opioid options.
Market Dynamics
Drivers
Demand for Non-Opioid Pain Drug products is supported by the persistent clinical burden of acute and chronic pain and by efforts to minimize unnecessary opioid exposure where effective alternatives are available. Non-opioid therapies already play an established role in common acute pain conditions, including musculoskeletal injuries, back pain and minor procedural pain, while acetaminophen, oral and topical NSAIDs and other non-opioid medicines remain widely integrated into routine treatment pathways. Clinical practice is increasingly emphasizing treatment selection according to pain type, expected duration, patient risk factors and functional goals rather than relying on a single analgesic class. This creates a broad demand base covering both consumer self-care products and prescription therapies. Perioperative care represents an additional driver as hospitals and clinicians increasingly use multimodal analgesic strategies combining systemic medicines with long-acting or site-specific local therapies to improve pain control while reducing reliance on opioid rescue medication.
Restraints
The principal limitation of the Non-Opioid Pain Drug market is that non-opioid does not mean clinically unrestricted. Established drug classes have well-defined dosing, contraindication and tolerability considerations that limit their use in particular patient populations. NSAIDs, for example, are associated with gastrointestinal and cardiovascular risks that become particularly relevant in older patients, patients with underlying disease and prolonged treatment settings. Other therapeutic classes similarly require patient-specific assessment and may not provide adequate analgesia for every pain severity or mechanism. At the commercial level, many traditional non-opioid analgesics are mature and highly genericized, creating strong price competition and limiting differentiation for standard formulations. Conversely, newer proprietary therapies may face higher treatment costs, reimbursement scrutiny and formulary barriers. The market consequently operates between two pressures: commoditization in established drug classes and the need for newer therapies to demonstrate sufficient clinical and economic value to justify premium positioning.
Opportunities
The most important opportunity lies in expanding the therapeutic space between conventional first-line analgesics and opioid therapy. Mechanism-specific oral medicines, prolonged local anesthetics, topical and transdermal therapies and rational combination products provide multiple routes for companies to address this gap. Acute moderate-to-severe pain is becoming particularly important because successful non-opioid products can potentially participate in treatment settings historically associated with substantial opioid use. The emergence of peripheral sodium channel pain signal inhibition demonstrates the potential for fundamentally new analgesic mechanisms, while extended-duration local therapies create opportunities in surgery and procedure-related pain. Additional opportunities exist in neuropathic pain, musculoskeletal disorders and targeted topical treatment, where patient heterogeneity favors differentiated therapeutic approaches. Combination products also offer potential to improve onset, duration or multimodal efficacy without relying on opioid components, supporting continued product reformulation and lifecycle innovation across both prescription and consumer-health markets.
Challenges
A central challenge for the Non-Opioid Pain Drug industry is translating pharmacological innovation into clinically meaningful advantages across highly heterogeneous pain conditions. Pain intensity is subjective, treatment response differs substantially among patients, and acute, inflammatory, neuropathic and postoperative pain involve different biological mechanisms. A therapy that performs well in one setting therefore cannot automatically establish broad value across the entire pain market. New prescription products must demonstrate not only statistically significant pain reduction but also clinically relevant improvements in duration, tolerability, functional recovery, opioid-sparing potential or ease of use. Companies must then secure reimbursement, hospital formulary access, physician adoption and patient acceptance while competing against inexpensive generic analgesics. Long development timelines and demanding clinical endpoints further increase commercialization risk. As the number of non-opioid approaches expands, differentiation will increasingly depend on clearly identifying the pain population, treatment setting and clinical value proposition in which each therapy provides a meaningful advantage.
Industry Chain Analysis
The upstream portion of the Non-Opioid Pain Drug industry consists primarily of active pharmaceutical ingredients, pharmaceutical intermediates, excipients and specialized formulation or drug-delivery materials. Conventional oral analgesics rely heavily on mature API manufacturing and large-scale solid-dose production, making manufacturing efficiency, quality control and supply security important competitive factors. More differentiated products introduce additional technical requirements, including sustained-release technologies, liposomal delivery systems, transdermal matrices, topical penetration systems and specialized injectable formulations. These technologies increase formulation complexity and can shift value creation away from the active ingredient alone toward proprietary delivery platforms, manufacturing know-how and intellectual property.
The midstream encompasses formulation development, clinical development, regulatory approval, commercial manufacturing, brand management and lifecycle management. Downstream channels differ significantly by product positioning: over-the-counter analgesics depend heavily on pharmacies, retail and consumer-health distribution, while prescription products rely more strongly on hospitals, physicians, specialty pharmacy and institutional formularies. In postoperative applications, adoption is closely linked to surgical protocols and hospital pain-management pathways. The value chain is therefore bifurcated. Mature generic products derive competitive advantage from manufacturing scale, procurement efficiency and channel coverage, whereas innovative non-opioid therapies capture value through differentiated mechanisms, longer duration of action, targeted delivery, clinical evidence and intellectual-property protection.
Segment Insights
From a Type perspective, acetaminophen/paracetamol and NSAIDs represent the broadest foundation of the Non-Opioid Pain Drug market because of their established role across common acute, inflammatory, dental, musculoskeletal and self-treated pain. Selective COX-2 inhibitors occupy a more differentiated anti-inflammatory position, while local anesthetic analgesics have particular relevance in procedural and postoperative settings. Sodium channel pain signal inhibitors represent an emerging mechanism-oriented segment following the introduction of a first-in-class therapy for moderate-to-severe acute pain. Capsaicin-based products, anticonvulsant analgesics and antidepressant analgesics address more specialized pain mechanisms, particularly neuropathic and chronic pain conditions. The market is consequently becoming more segmented by pain biology rather than being defined only by analgesic strength.
Across Class, Group and Sort, single-agent drugs continue to provide the core treatment base, while combination products offer opportunities for complementary mechanisms and differentiated duration or onset of action. Prescription products are particularly important where pain severity, comorbidity or specialized delivery requires physician supervision, whereas OTC medicines remain central to everyday pain self-management. Oral formulations provide the widest routine-use platform, but injectable, topical and transdermal products allow treatment to become more site-specific and can address patients or clinical scenarios where systemic exposure is less desirable. The development of prolonged local analgesia and increasingly differentiated topical pain products suggests that formulation technology is becoming an important source of competitive separation alongside active pharmaceutical innovation.
Downstream Market Opportunities
Downstream demand for Non-Opioid Pain Drug products spans everyday self-treated pain and highly managed clinical pain pathways. Musculoskeletal pain, arthritis, back pain, headache and migraine, dental pain and menstrual pain provide recurring demand for accessible oral and topical products, while neuropathic pain requires more mechanism-specific pharmacotherapy. Postoperative pain represents one of the most strategically important opportunities because treatment decisions occur within structured hospital and surgical protocols where duration of analgesia, recovery quality and opioid-sparing potential can materially influence product selection. Injury and trauma pain also support short-term acute treatment demand, while selected cancer-related pain settings create opportunities for non-opioid medicines as components of multimodal therapy. The major commercial opportunity is therefore not a single application, but the progressive segmentation of pain management according to etiology, severity, duration and treatment setting.
Regional Insights
North America is an important innovation and commercialization market for Non-Opioid Pain Drug products, particularly for novel prescription mechanisms and perioperative pain-management therapies. Recent regulatory progress in peripheral sodium channel inhibition and continued development of extended-duration local analgesics demonstrate active efforts to broaden non-opioid treatment options in acute and postoperative pain. The region also has a mature consumer-health market supported by established OTC analgesic brands. Europe similarly represents a mature market, with significant use of both prescription and OTC pain medicines and opportunities centered on formulation differentiation, localized pain treatment and improved patient selection.
Asia-Pacific combines a large base of conventional analgesic use with expanding demand for branded OTC products, prescription pain management and differentiated formulations. Japan has a well-developed topical and transdermal pain-treatment tradition, while China combines large-scale generic pharmaceutical manufacturing with increasing development of innovative and higher-value prescription therapies. Across emerging markets, affordability and broad distribution remain critical, meaning established oral drugs are likely to retain substantial importance even as more specialized products expand. Regional competition will therefore remain structurally different: innovation and premium prescription therapies are more prominent in developed markets, while manufacturing economics, accessibility and channel penetration remain especially influential in price-sensitive markets.
Competitive Landscape Analysis
The competitive landscape is structurally diversified rather than dominated by one type of pharmaceutical company. Within the confirmed company set, Kenvue, Haleon and Bayer participate strongly through established consumer pain-care portfolios, while Vertex Pharmaceuticals Incorporated, Pfizer Inc., Pacira BioSciences, Inc., Heron Therapeutics, Inc., Scilex Holding Company and Gr?nenthal GmbH represent prescription or specialty-pharma approaches to differentiated pain management. Hisamitsu Pharmaceutical Co., Inc., Daiichi Sankyo Healthcare Co., Ltd. and AFT Pharmaceuticals Limited add regional and formulation-focused positions, while Viatris Inc., Teva Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd. and Sun Pharmaceutical Industries Ltd. participate through broad pharmaceutical portfolios and large-scale manufacturing capabilities; Jiangsu Hengrui Pharmaceuticals Co., Ltd. represents the confirmed Chinese participant in the research scope. Competition therefore occurs across several dimensions simultaneously: consumer brand recognition, manufacturing scale, prescription access, formulation technology, proprietary mechanisms, clinical evidence and distribution reach. Recent progress in selective peripheral pain signaling and prolonged local analgesia indicates that future competitive differentiation is likely to rely increasingly on mechanism specificity and demonstrable clinical value rather than simple expansion of conventional analgesic portfolios.
Report Scope
LPI (LP Information)' newest research report, the “Non-Opioid Pain Drug Industry Forecast” looks at past sales and reviews total world Non-Opioid Pain Drug sales in 2025, providing a comprehensive analysis by region and market sector of projected Non-Opioid Pain Drug sales for 2026 through 2032. With Non-Opioid Pain Drug sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Non-Opioid Pain Drug industry.
This Insight Report provides a comprehensive analysis of the global Non-Opioid Pain Drug landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Non-Opioid Pain Drug portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Non-Opioid Pain Drug market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Non-Opioid Pain Drug and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Non-Opioid Pain Drug.
This report presents a comprehensive overview, market shares, and growth opportunities of Non-Opioid Pain Drug market by product type, application, key players and key regions and countries.
Market Segmentation
Segmentation by Type:
- Acetaminophen/Paracetamol
- Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
- Selective COX-2 Inhibitors
- Sodium Channel Pain Signal Inhibitors
- Local Anesthetic Analgesics
- Other
Segmentation by Drug Ingredients:
- Single-Agent Drugs
- Combination Drugs
Segmentation by Route of Administration:
- Oral Drugs
- Injectable Drugs
- Topical Drugs
Segmentation by Application:
- Postoperative Pain
- Musculoskeletal Pain
- Arthritis Pain
- Neuropathic Pain
- Headache and Migraine
- Other
This report also splits the market by region:
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Vertex Pharmaceuticals
- Kenvue
- Haleon
- Bayer
- Pfizer
- Pacira BioSciences
- Heron Therapeutics
- Scilex Holding
- Gr?nenthal
- Hisamitsu Pharmaceutical
- Daiichi Sankyo
- AFT Pharmaceuticals
- Viatris
- Teva Pharmaceutical
- Dr. Reddy's
- Sun Pharmaceutical
- Jiangsu Hengrui
- Johnson & Johnson
- Hubei Hendi Pharmaceutical
- CSPC Pharmaceutical Group
- Simcere Pharmaceutical
- Qilu Pharmaceutical
- Yichang Humanwell Pharmaceutical
- Tongfang Pharma
- Fresenius
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Non-Opioid Pain Drug Market Size (2021-2032)
2.1.2 Non-Opioid Pain Drug Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Non-Opioid Pain Drug by Country/Region (2021, 2025 & 2032)
2.2 Non-Opioid Pain Drug Segment by Type
2.2.1 Acetaminophen/Paracetamol
2.2.2 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
2.2.3 Selective COX-2 Inhibitors
2.2.4 Sodium Channel Pain Signal Inhibitors
2.2.5 Local Anesthetic Analgesics
2.2.6 Other
2.2.7 Non-Opioid Pain Drug Market Size by Type
2.2.7.1 Non-Opioid Pain Drug Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.7.2 Global Non-Opioid Pain Drug Market Size Market Share by Type (2021-2026)
2.3 Non-Opioid Pain Drug Segment by Drug Ingredients
2.3.1 Single-Agent Drugs
2.3.2 Combination Drugs
2.3.3 Non-Opioid Pain Drug Market Size by Drug Ingredients
2.3.3.1 Non-Opioid Pain Drug Market Size CAGR by Drug Ingredients (2021 VS 2025 VS 2032)
2.3.3.2 Global Non-Opioid Pain Drug Market Size Market Share by Drug Ingredients (2021-2026)
2.4 Non-Opioid Pain Drug Segment by Route of Administration
2.4.1 Oral Drugs
2.4.2 Injectable Drugs
2.4.3 Topical Drugs
2.4.4 Non-Opioid Pain Drug Market Size by Route of Administration
2.4.4.1 Non-Opioid Pain Drug Market Size CAGR by Route of Administration (2021 VS 2025 VS 2032)
2.4.4.2 Global Non-Opioid Pain Drug Market Size Market Share by Route of Administration (2021-2026)
2.5 Non-Opioid Pain Drug Segment by Application
2.5.1 Postoperative Pain
2.5.2 Musculoskeletal Pain
2.5.3 Arthritis Pain
2.5.4 Neuropathic Pain
2.5.5 Headache and Migraine
2.5.6 Other
2.5.7 Non-Opioid Pain Drug Market Size by Application
2.5.7.1 Non-Opioid Pain Drug Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.7.2 Global Non-Opioid Pain Drug Market Size Market Share by Application (2021-2026)
3 NON-OPIOID PAIN DRUG MARKET SIZE BY PLAYER
3.1 Non-Opioid Pain Drug Market Size Market Share by Player
3.1.1 Global Non-Opioid Pain Drug Revenue by Player (2021-2026)
3.1.2 Global Non-Opioid Pain Drug Revenue Market Share by Player (2021-2026)
3.2 Global Non-Opioid Pain Drug Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 NON-OPIOID PAIN DRUG BY REGION
4.1 Non-Opioid Pain Drug Market Size by Region (2021-2026)
4.2 Global Non-Opioid Pain Drug Annual Revenue by Country/Region (2021-2026)
4.3 Americas Non-Opioid Pain Drug Market Size Growth (2021-2026)
4.4 APAC Non-Opioid Pain Drug Market Size Growth (2021-2026)
4.5 Europe Non-Opioid Pain Drug Market Size Growth (2021-2026)
4.6 Middle East & Africa Non-Opioid Pain Drug Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Non-Opioid Pain Drug Market Size by Country (2021-2026)
5.2 Americas Non-Opioid Pain Drug Market Size by Type (2021-2026)
5.3 Americas Non-Opioid Pain Drug Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Non-Opioid Pain Drug Market Size by Region (2021-2026)
6.2 APAC Non-Opioid Pain Drug Market Size by Type (2021-2026)
6.3 APAC Non-Opioid Pain Drug Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Non-Opioid Pain Drug Market Size by Country (2021-2026)
7.2 Europe Non-Opioid Pain Drug Market Size by Type (2021-2026)
7.3 Europe Non-Opioid Pain Drug Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Non-Opioid Pain Drug by Region (2021-2026)
8.2 Middle East & Africa Non-Opioid Pain Drug Market Size by Type (2021-2026)
8.3 Middle East & Africa Non-Opioid Pain Drug Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL NON-OPIOID PAIN DRUG MARKET FORECAST
10.1 Global Non-Opioid Pain Drug Forecast by Region (2027-2032)
10.1.1 Global Non-Opioid Pain Drug Forecast by Region (2027-2032)
10.1.2 Americas Non-Opioid Pain Drug Forecast
10.1.3 APAC Non-Opioid Pain Drug Forecast
10.1.4 Europe Non-Opioid Pain Drug Forecast
10.1.5 Middle East & Africa Non-Opioid Pain Drug Forecast
10.2 Americas Non-Opioid Pain Drug Forecast by Country (2027-2032)
10.2.1 United States Market Non-Opioid Pain Drug Forecast
10.2.2 Canada Market Non-Opioid Pain Drug Forecast
10.2.3 Mexico Market Non-Opioid Pain Drug Forecast
10.2.4 Brazil Market Non-Opioid Pain Drug Forecast
10.3 APAC Non-Opioid Pain Drug Forecast by Region (2027-2032)
10.3.1 China Non-Opioid Pain Drug Market Forecast
10.3.2 Japan Market Non-Opioid Pain Drug Forecast
10.3.3 Korea Market Non-Opioid Pain Drug Forecast
10.3.4 Southeast Asia Market Non-Opioid Pain Drug Forecast
10.3.5 India Market Non-Opioid Pain Drug Forecast
10.3.6 Australia Market Non-Opioid Pain Drug Forecast
10.4 Europe Non-Opioid Pain Drug Forecast by Country (2027-2032)
10.4.1 Germany Market Non-Opioid Pain Drug Forecast
10.4.2 France Market Non-Opioid Pain Drug Forecast
10.4.3 UK Market Non-Opioid Pain Drug Forecast
10.4.4 Italy Market Non-Opioid Pain Drug Forecast
10.4.5 Russia Market Non-Opioid Pain Drug Forecast
10.5 Middle East & Africa Non-Opioid Pain Drug Forecast by Region (2027-2032)
10.5.1 Egypt Market Non-Opioid Pain Drug Forecast
10.5.2 South Africa Market Non-Opioid Pain Drug Forecast
10.5.3 Israel Market Non-Opioid Pain Drug Forecast
10.5.4 Turkey Market Non-Opioid Pain Drug Forecast
10.6 Global Non-Opioid Pain Drug Forecast by Type (2027-2032)
10.7 Global Non-Opioid Pain Drug Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Non-Opioid Pain Drug Forecast
11 KEY PLAYERS ANALYSIS
11.1 Vertex Pharmaceuticals
11.1.1 Vertex Pharmaceuticals Company Information
11.1.2 Vertex Pharmaceuticals Non-Opioid Pain Drug Product Offered
11.1.3 Vertex Pharmaceuticals Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Vertex Pharmaceuticals Main Business Overview
11.1.5 Vertex Pharmaceuticals Latest Developments
11.2 Kenvue
11.2.1 Kenvue Company Information
11.2.2 Kenvue Non-Opioid Pain Drug Product Offered
11.2.3 Kenvue Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Kenvue Main Business Overview
11.2.5 Kenvue Latest Developments
11.3 Haleon
11.3.1 Haleon Company Information
11.3.2 Haleon Non-Opioid Pain Drug Product Offered
11.3.3 Haleon Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Haleon Main Business Overview
11.3.5 Haleon Latest Developments
11.4 Bayer
11.4.1 Bayer Company Information
11.4.2 Bayer Non-Opioid Pain Drug Product Offered
11.4.3 Bayer Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Bayer Main Business Overview
11.4.5 Bayer Latest Developments
11.5 Pfizer
11.5.1 Pfizer Company Information
11.5.2 Pfizer Non-Opioid Pain Drug Product Offered
11.5.3 Pfizer Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Pfizer Main Business Overview
11.5.5 Pfizer Latest Developments
11.6 Pacira BioSciences
11.6.1 Pacira BioSciences Company Information
11.6.2 Pacira BioSciences Non-Opioid Pain Drug Product Offered
11.6.3 Pacira BioSciences Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Pacira BioSciences Main Business Overview
11.6.5 Pacira BioSciences Latest Developments
11.7 Heron Therapeutics
11.7.1 Heron Therapeutics Company Information
11.7.2 Heron Therapeutics Non-Opioid Pain Drug Product Offered
11.7.3 Heron Therapeutics Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Heron Therapeutics Main Business Overview
11.7.5 Heron Therapeutics Latest Developments
11.8 Scilex Holding
11.8.1 Scilex Holding Company Information
11.8.2 Scilex Holding Non-Opioid Pain Drug Product Offered
11.8.3 Scilex Holding Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Scilex Holding Main Business Overview
11.8.5 Scilex Holding Latest Developments
11.9 Gr?nenthal
11.9.1 Gr?nenthal Company Information
11.9.2 Gr?nenthal Non-Opioid Pain Drug Product Offered
11.9.3 Gr?nenthal Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Gr?nenthal Main Business Overview
11.9.5 Gr?nenthal Latest Developments
11.10 Hisamitsu Pharmaceutical
11.10.1 Hisamitsu Pharmaceutical Company Information
11.10.2 Hisamitsu Pharmaceutical Non-Opioid Pain Drug Product Offered
11.10.3 Hisamitsu Pharmaceutical Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Hisamitsu Pharmaceutical Main Business Overview
11.10.5 Hisamitsu Pharmaceutical Latest Developments
11.11 Daiichi Sankyo
11.11.1 Daiichi Sankyo Company Information
11.11.2 Daiichi Sankyo Non-Opioid Pain Drug Product Offered
11.11.3 Daiichi Sankyo Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Daiichi Sankyo Main Business Overview
11.11.5 Daiichi Sankyo Latest Developments
11.12 AFT Pharmaceuticals
11.12.1 AFT Pharmaceuticals Company Information
11.12.2 AFT Pharmaceuticals Non-Opioid Pain Drug Product Offered
11.12.3 AFT Pharmaceuticals Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 AFT Pharmaceuticals Main Business Overview
11.12.5 AFT Pharmaceuticals Latest Developments
11.13 Viatris
11.13.1 Viatris Company Information
11.13.2 Viatris Non-Opioid Pain Drug Product Offered
11.13.3 Viatris Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Viatris Main Business Overview
11.13.5 Viatris Latest Developments
11.14 Teva Pharmaceutical
11.14.1 Teva Pharmaceutical Company Information
11.14.2 Teva Pharmaceutical Non-Opioid Pain Drug Product Offered
11.14.3 Teva Pharmaceutical Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Teva Pharmaceutical Main Business Overview
11.14.5 Teva Pharmaceutical Latest Developments
11.15 Dr. Reddy's
11.15.1 Dr. Reddy's Company Information
11.15.2 Dr. Reddy's Non-Opioid Pain Drug Product Offered
11.15.3 Dr. Reddy's Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Dr. Reddy's Main Business Overview
11.15.5 Dr. Reddy's Latest Developments
11.16 Sun Pharmaceutical
11.16.1 Sun Pharmaceutical Company Information
11.16.2 Sun Pharmaceutical Non-Opioid Pain Drug Product Offered
11.16.3 Sun Pharmaceutical Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 Sun Pharmaceutical Main Business Overview
11.16.5 Sun Pharmaceutical Latest Developments
11.17 Jiangsu Hengrui
11.17.1 Jiangsu Hengrui Company Information
11.17.2 Jiangsu Hengrui Non-Opioid Pain Drug Product Offered
11.17.3 Jiangsu Hengrui Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Jiangsu Hengrui Main Business Overview
11.17.5 Jiangsu Hengrui Latest Developments
11.18 Johnson & Johnson
11.18.1 Johnson & Johnson Company Information
11.18.2 Johnson & Johnson Non-Opioid Pain Drug Product Offered
11.18.3 Johnson & Johnson Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 Johnson & Johnson Main Business Overview
11.18.5 Johnson & Johnson Latest Developments
11.19 Hubei Hendi Pharmaceutical
11.19.1 Hubei Hendi Pharmaceutical Company Information
11.19.2 Hubei Hendi Pharmaceutical Non-Opioid Pain Drug Product Offered
11.19.3 Hubei Hendi Pharmaceutical Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.19.4 Hubei Hendi Pharmaceutical Main Business Overview
11.19.5 Hubei Hendi Pharmaceutical Latest Developments
11.20 CSPC Pharmaceutical Group
11.20.1 CSPC Pharmaceutical Group Company Information
11.20.2 CSPC Pharmaceutical Group Non-Opioid Pain Drug Product Offered
11.20.3 CSPC Pharmaceutical Group Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.20.4 CSPC Pharmaceutical Group Main Business Overview
11.20.5 CSPC Pharmaceutical Group Latest Developments
11.21 Simcere Pharmaceutical
11.21.1 Simcere Pharmaceutical Company Information
11.21.2 Simcere Pharmaceutical Non-Opioid Pain Drug Product Offered
11.21.3 Simcere Pharmaceutical Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.21.4 Simcere Pharmaceutical Main Business Overview
11.21.5 Simcere Pharmaceutical Latest Developments
11.22 Qilu Pharmaceutical
11.22.1 Qilu Pharmaceutical Company Information
11.22.2 Qilu Pharmaceutical Non-Opioid Pain Drug Product Offered
11.22.3 Qilu Pharmaceutical Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.22.4 Qilu Pharmaceutical Main Business Overview
11.22.5 Qilu Pharmaceutical Latest Developments
11.23 Yichang Humanwell Pharmaceutical
11.23.1 Yichang Humanwell Pharmaceutical Company Information
11.23.2 Yichang Humanwell Pharmaceutical Non-Opioid Pain Drug Product Offered
11.23.3 Yichang Humanwell Pharmaceutical Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.23.4 Yichang Humanwell Pharmaceutical Main Business Overview
11.23.5 Yichang Humanwell Pharmaceutical Latest Developments
11.24 Tongfang Pharma
11.24.1 Tongfang Pharma Company Information
11.24.2 Tongfang Pharma Non-Opioid Pain Drug Product Offered
11.24.3 Tongfang Pharma Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.24.4 Tongfang Pharma Main Business Overview
11.24.5 Tongfang Pharma Latest Developments
11.25 Fresenius
11.25.1 Fresenius Company Information
11.25.2 Fresenius Non-Opioid Pain Drug Product Offered
11.25.3 Fresenius Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.25.4 Fresenius Main Business Overview
11.25.5 Fresenius Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Non-Opioid Pain Drug Market Size (2021-2032)
2.1.2 Non-Opioid Pain Drug Market Size CAGR by Region (2021 VS 2025 VS 2032)
2.1.3 World Current & Future Analysis for Non-Opioid Pain Drug by Country/Region (2021, 2025 & 2032)
2.2 Non-Opioid Pain Drug Segment by Type
2.2.1 Acetaminophen/Paracetamol
2.2.2 Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
2.2.3 Selective COX-2 Inhibitors
2.2.4 Sodium Channel Pain Signal Inhibitors
2.2.5 Local Anesthetic Analgesics
2.2.6 Other
2.2.7 Non-Opioid Pain Drug Market Size by Type
2.2.7.1 Non-Opioid Pain Drug Market Size CAGR by Type (2021 VS 2025 VS 2032)
2.2.7.2 Global Non-Opioid Pain Drug Market Size Market Share by Type (2021-2026)
2.3 Non-Opioid Pain Drug Segment by Drug Ingredients
2.3.1 Single-Agent Drugs
2.3.2 Combination Drugs
2.3.3 Non-Opioid Pain Drug Market Size by Drug Ingredients
2.3.3.1 Non-Opioid Pain Drug Market Size CAGR by Drug Ingredients (2021 VS 2025 VS 2032)
2.3.3.2 Global Non-Opioid Pain Drug Market Size Market Share by Drug Ingredients (2021-2026)
2.4 Non-Opioid Pain Drug Segment by Route of Administration
2.4.1 Oral Drugs
2.4.2 Injectable Drugs
2.4.3 Topical Drugs
2.4.4 Non-Opioid Pain Drug Market Size by Route of Administration
2.4.4.1 Non-Opioid Pain Drug Market Size CAGR by Route of Administration (2021 VS 2025 VS 2032)
2.4.4.2 Global Non-Opioid Pain Drug Market Size Market Share by Route of Administration (2021-2026)
2.5 Non-Opioid Pain Drug Segment by Application
2.5.1 Postoperative Pain
2.5.2 Musculoskeletal Pain
2.5.3 Arthritis Pain
2.5.4 Neuropathic Pain
2.5.5 Headache and Migraine
2.5.6 Other
2.5.7 Non-Opioid Pain Drug Market Size by Application
2.5.7.1 Non-Opioid Pain Drug Market Size CAGR by Application (2021 VS 2025 VS 2032)
2.5.7.2 Global Non-Opioid Pain Drug Market Size Market Share by Application (2021-2026)
3 NON-OPIOID PAIN DRUG MARKET SIZE BY PLAYER
3.1 Non-Opioid Pain Drug Market Size Market Share by Player
3.1.1 Global Non-Opioid Pain Drug Revenue by Player (2021-2026)
3.1.2 Global Non-Opioid Pain Drug Revenue Market Share by Player (2021-2026)
3.2 Global Non-Opioid Pain Drug Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 NON-OPIOID PAIN DRUG BY REGION
4.1 Non-Opioid Pain Drug Market Size by Region (2021-2026)
4.2 Global Non-Opioid Pain Drug Annual Revenue by Country/Region (2021-2026)
4.3 Americas Non-Opioid Pain Drug Market Size Growth (2021-2026)
4.4 APAC Non-Opioid Pain Drug Market Size Growth (2021-2026)
4.5 Europe Non-Opioid Pain Drug Market Size Growth (2021-2026)
4.6 Middle East & Africa Non-Opioid Pain Drug Market Size Growth (2021-2026)
5 AMERICAS
5.1 Americas Non-Opioid Pain Drug Market Size by Country (2021-2026)
5.2 Americas Non-Opioid Pain Drug Market Size by Type (2021-2026)
5.3 Americas Non-Opioid Pain Drug Market Size by Application (2021-2026)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Non-Opioid Pain Drug Market Size by Region (2021-2026)
6.2 APAC Non-Opioid Pain Drug Market Size by Type (2021-2026)
6.3 APAC Non-Opioid Pain Drug Market Size by Application (2021-2026)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Non-Opioid Pain Drug Market Size by Country (2021-2026)
7.2 Europe Non-Opioid Pain Drug Market Size by Type (2021-2026)
7.3 Europe Non-Opioid Pain Drug Market Size by Application (2021-2026)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Non-Opioid Pain Drug by Region (2021-2026)
8.2 Middle East & Africa Non-Opioid Pain Drug Market Size by Type (2021-2026)
8.3 Middle East & Africa Non-Opioid Pain Drug Market Size by Application (2021-2026)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL NON-OPIOID PAIN DRUG MARKET FORECAST
10.1 Global Non-Opioid Pain Drug Forecast by Region (2027-2032)
10.1.1 Global Non-Opioid Pain Drug Forecast by Region (2027-2032)
10.1.2 Americas Non-Opioid Pain Drug Forecast
10.1.3 APAC Non-Opioid Pain Drug Forecast
10.1.4 Europe Non-Opioid Pain Drug Forecast
10.1.5 Middle East & Africa Non-Opioid Pain Drug Forecast
10.2 Americas Non-Opioid Pain Drug Forecast by Country (2027-2032)
10.2.1 United States Market Non-Opioid Pain Drug Forecast
10.2.2 Canada Market Non-Opioid Pain Drug Forecast
10.2.3 Mexico Market Non-Opioid Pain Drug Forecast
10.2.4 Brazil Market Non-Opioid Pain Drug Forecast
10.3 APAC Non-Opioid Pain Drug Forecast by Region (2027-2032)
10.3.1 China Non-Opioid Pain Drug Market Forecast
10.3.2 Japan Market Non-Opioid Pain Drug Forecast
10.3.3 Korea Market Non-Opioid Pain Drug Forecast
10.3.4 Southeast Asia Market Non-Opioid Pain Drug Forecast
10.3.5 India Market Non-Opioid Pain Drug Forecast
10.3.6 Australia Market Non-Opioid Pain Drug Forecast
10.4 Europe Non-Opioid Pain Drug Forecast by Country (2027-2032)
10.4.1 Germany Market Non-Opioid Pain Drug Forecast
10.4.2 France Market Non-Opioid Pain Drug Forecast
10.4.3 UK Market Non-Opioid Pain Drug Forecast
10.4.4 Italy Market Non-Opioid Pain Drug Forecast
10.4.5 Russia Market Non-Opioid Pain Drug Forecast
10.5 Middle East & Africa Non-Opioid Pain Drug Forecast by Region (2027-2032)
10.5.1 Egypt Market Non-Opioid Pain Drug Forecast
10.5.2 South Africa Market Non-Opioid Pain Drug Forecast
10.5.3 Israel Market Non-Opioid Pain Drug Forecast
10.5.4 Turkey Market Non-Opioid Pain Drug Forecast
10.6 Global Non-Opioid Pain Drug Forecast by Type (2027-2032)
10.7 Global Non-Opioid Pain Drug Forecast by Application (2027-2032)
10.7.1 GCC Countries Market Non-Opioid Pain Drug Forecast
11 KEY PLAYERS ANALYSIS
11.1 Vertex Pharmaceuticals
11.1.1 Vertex Pharmaceuticals Company Information
11.1.2 Vertex Pharmaceuticals Non-Opioid Pain Drug Product Offered
11.1.3 Vertex Pharmaceuticals Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.1.4 Vertex Pharmaceuticals Main Business Overview
11.1.5 Vertex Pharmaceuticals Latest Developments
11.2 Kenvue
11.2.1 Kenvue Company Information
11.2.2 Kenvue Non-Opioid Pain Drug Product Offered
11.2.3 Kenvue Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.2.4 Kenvue Main Business Overview
11.2.5 Kenvue Latest Developments
11.3 Haleon
11.3.1 Haleon Company Information
11.3.2 Haleon Non-Opioid Pain Drug Product Offered
11.3.3 Haleon Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.3.4 Haleon Main Business Overview
11.3.5 Haleon Latest Developments
11.4 Bayer
11.4.1 Bayer Company Information
11.4.2 Bayer Non-Opioid Pain Drug Product Offered
11.4.3 Bayer Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.4.4 Bayer Main Business Overview
11.4.5 Bayer Latest Developments
11.5 Pfizer
11.5.1 Pfizer Company Information
11.5.2 Pfizer Non-Opioid Pain Drug Product Offered
11.5.3 Pfizer Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.5.4 Pfizer Main Business Overview
11.5.5 Pfizer Latest Developments
11.6 Pacira BioSciences
11.6.1 Pacira BioSciences Company Information
11.6.2 Pacira BioSciences Non-Opioid Pain Drug Product Offered
11.6.3 Pacira BioSciences Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.6.4 Pacira BioSciences Main Business Overview
11.6.5 Pacira BioSciences Latest Developments
11.7 Heron Therapeutics
11.7.1 Heron Therapeutics Company Information
11.7.2 Heron Therapeutics Non-Opioid Pain Drug Product Offered
11.7.3 Heron Therapeutics Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.7.4 Heron Therapeutics Main Business Overview
11.7.5 Heron Therapeutics Latest Developments
11.8 Scilex Holding
11.8.1 Scilex Holding Company Information
11.8.2 Scilex Holding Non-Opioid Pain Drug Product Offered
11.8.3 Scilex Holding Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.8.4 Scilex Holding Main Business Overview
11.8.5 Scilex Holding Latest Developments
11.9 Gr?nenthal
11.9.1 Gr?nenthal Company Information
11.9.2 Gr?nenthal Non-Opioid Pain Drug Product Offered
11.9.3 Gr?nenthal Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.9.4 Gr?nenthal Main Business Overview
11.9.5 Gr?nenthal Latest Developments
11.10 Hisamitsu Pharmaceutical
11.10.1 Hisamitsu Pharmaceutical Company Information
11.10.2 Hisamitsu Pharmaceutical Non-Opioid Pain Drug Product Offered
11.10.3 Hisamitsu Pharmaceutical Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.10.4 Hisamitsu Pharmaceutical Main Business Overview
11.10.5 Hisamitsu Pharmaceutical Latest Developments
11.11 Daiichi Sankyo
11.11.1 Daiichi Sankyo Company Information
11.11.2 Daiichi Sankyo Non-Opioid Pain Drug Product Offered
11.11.3 Daiichi Sankyo Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.11.4 Daiichi Sankyo Main Business Overview
11.11.5 Daiichi Sankyo Latest Developments
11.12 AFT Pharmaceuticals
11.12.1 AFT Pharmaceuticals Company Information
11.12.2 AFT Pharmaceuticals Non-Opioid Pain Drug Product Offered
11.12.3 AFT Pharmaceuticals Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.12.4 AFT Pharmaceuticals Main Business Overview
11.12.5 AFT Pharmaceuticals Latest Developments
11.13 Viatris
11.13.1 Viatris Company Information
11.13.2 Viatris Non-Opioid Pain Drug Product Offered
11.13.3 Viatris Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.13.4 Viatris Main Business Overview
11.13.5 Viatris Latest Developments
11.14 Teva Pharmaceutical
11.14.1 Teva Pharmaceutical Company Information
11.14.2 Teva Pharmaceutical Non-Opioid Pain Drug Product Offered
11.14.3 Teva Pharmaceutical Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.14.4 Teva Pharmaceutical Main Business Overview
11.14.5 Teva Pharmaceutical Latest Developments
11.15 Dr. Reddy's
11.15.1 Dr. Reddy's Company Information
11.15.2 Dr. Reddy's Non-Opioid Pain Drug Product Offered
11.15.3 Dr. Reddy's Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.15.4 Dr. Reddy's Main Business Overview
11.15.5 Dr. Reddy's Latest Developments
11.16 Sun Pharmaceutical
11.16.1 Sun Pharmaceutical Company Information
11.16.2 Sun Pharmaceutical Non-Opioid Pain Drug Product Offered
11.16.3 Sun Pharmaceutical Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.16.4 Sun Pharmaceutical Main Business Overview
11.16.5 Sun Pharmaceutical Latest Developments
11.17 Jiangsu Hengrui
11.17.1 Jiangsu Hengrui Company Information
11.17.2 Jiangsu Hengrui Non-Opioid Pain Drug Product Offered
11.17.3 Jiangsu Hengrui Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.17.4 Jiangsu Hengrui Main Business Overview
11.17.5 Jiangsu Hengrui Latest Developments
11.18 Johnson & Johnson
11.18.1 Johnson & Johnson Company Information
11.18.2 Johnson & Johnson Non-Opioid Pain Drug Product Offered
11.18.3 Johnson & Johnson Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.18.4 Johnson & Johnson Main Business Overview
11.18.5 Johnson & Johnson Latest Developments
11.19 Hubei Hendi Pharmaceutical
11.19.1 Hubei Hendi Pharmaceutical Company Information
11.19.2 Hubei Hendi Pharmaceutical Non-Opioid Pain Drug Product Offered
11.19.3 Hubei Hendi Pharmaceutical Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.19.4 Hubei Hendi Pharmaceutical Main Business Overview
11.19.5 Hubei Hendi Pharmaceutical Latest Developments
11.20 CSPC Pharmaceutical Group
11.20.1 CSPC Pharmaceutical Group Company Information
11.20.2 CSPC Pharmaceutical Group Non-Opioid Pain Drug Product Offered
11.20.3 CSPC Pharmaceutical Group Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.20.4 CSPC Pharmaceutical Group Main Business Overview
11.20.5 CSPC Pharmaceutical Group Latest Developments
11.21 Simcere Pharmaceutical
11.21.1 Simcere Pharmaceutical Company Information
11.21.2 Simcere Pharmaceutical Non-Opioid Pain Drug Product Offered
11.21.3 Simcere Pharmaceutical Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.21.4 Simcere Pharmaceutical Main Business Overview
11.21.5 Simcere Pharmaceutical Latest Developments
11.22 Qilu Pharmaceutical
11.22.1 Qilu Pharmaceutical Company Information
11.22.2 Qilu Pharmaceutical Non-Opioid Pain Drug Product Offered
11.22.3 Qilu Pharmaceutical Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.22.4 Qilu Pharmaceutical Main Business Overview
11.22.5 Qilu Pharmaceutical Latest Developments
11.23 Yichang Humanwell Pharmaceutical
11.23.1 Yichang Humanwell Pharmaceutical Company Information
11.23.2 Yichang Humanwell Pharmaceutical Non-Opioid Pain Drug Product Offered
11.23.3 Yichang Humanwell Pharmaceutical Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.23.4 Yichang Humanwell Pharmaceutical Main Business Overview
11.23.5 Yichang Humanwell Pharmaceutical Latest Developments
11.24 Tongfang Pharma
11.24.1 Tongfang Pharma Company Information
11.24.2 Tongfang Pharma Non-Opioid Pain Drug Product Offered
11.24.3 Tongfang Pharma Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.24.4 Tongfang Pharma Main Business Overview
11.24.5 Tongfang Pharma Latest Developments
11.25 Fresenius
11.25.1 Fresenius Company Information
11.25.2 Fresenius Non-Opioid Pain Drug Product Offered
11.25.3 Fresenius Non-Opioid Pain Drug Revenue, Gross Margin and Market Share (2021-2026)
11.25.4 Fresenius Main Business Overview
11.25.5 Fresenius Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Non-Opioid Pain Drug Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Non-Opioid Pain Drug Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Acetaminophen/Paracetamol
Table 4. Major Players of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Table 5. Major Players of Selective COX-2 Inhibitors
Table 6. Major Players of Sodium Channel Pain Signal Inhibitors
Table 7. Major Players of Local Anesthetic Analgesics
Table 8. Major Players of Other
Table 9. Non-Opioid Pain Drug Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 10. Global Non-Opioid Pain Drug Market Size by Type (2021-2026) & ($ millions)
Table 11. Global Non-Opioid Pain Drug Market Size Market Share by Type (2021-2026)
Table 12. Major Players of Single-Agent Drugs
Table 13. Major Players of Combination Drugs
Table 14. Non-Opioid Pain Drug Market Size CAGR by Drug Ingredients (2021 VS 2025 VS 2032) & ($ millions)
Table 15. Global Non-Opioid Pain Drug Market Size by Drug Ingredients (2021-2026) & ($ millions)
Table 16. Global Non-Opioid Pain Drug Market Size Market Share by Drug Ingredients (2021-2026)
Table 17. Major Players of Oral Drugs
Table 18. Major Players of Injectable Drugs
Table 19. Major Players of Topical Drugs
Table 20. Non-Opioid Pain Drug Market Size CAGR by Route of Administration (2021 VS 2025 VS 2032) & ($ millions)
Table 21. Global Non-Opioid Pain Drug Market Size by Route of Administration (2021-2026) & ($ millions)
Table 22. Global Non-Opioid Pain Drug Market Size Market Share by Route of Administration (2021-2026)
Table 23. Non-Opioid Pain Drug Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 24. Global Non-Opioid Pain Drug Market Size by Application (2021-2026) & ($ millions)
Table 25. Global Non-Opioid Pain Drug Market Size Market Share by Application (2021-2026)
Table 26. Global Non-Opioid Pain Drug Revenue by Player (2021-2026) & ($ millions)
Table 27. Global Non-Opioid Pain Drug Revenue Market Share by Player (2021-2026)
Table 28. Non-Opioid Pain Drug Key Players Head office and Products Offered
Table 29. Non-Opioid Pain Drug Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 30. New Products and Potential Entrants
Table 31. Mergers & Acquisitions, Expansion
Table 32. Global Non-Opioid Pain Drug Market Size by Region (2021-2026) & ($ millions)
Table 33. Global Non-Opioid Pain Drug Market Size Market Share by Region (2021-2026)
Table 34. Global Non-Opioid Pain Drug Revenue by Country/Region (2021-2026) & ($ millions)
Table 35. Global Non-Opioid Pain Drug Revenue Market Share by Country/Region (2021-2026)
Table 36. Americas Non-Opioid Pain Drug Market Size by Country (2021-2026) & ($ millions)
Table 37. Americas Non-Opioid Pain Drug Market Size Market Share by Country (2021-2026)
Table 38. Americas Non-Opioid Pain Drug Market Size by Type (2021-2026) & ($ millions)
Table 39. Americas Non-Opioid Pain Drug Market Size Market Share by Type (2021-2026)
Table 40. Americas Non-Opioid Pain Drug Market Size by Application (2021-2026) & ($ millions)
Table 41. Americas Non-Opioid Pain Drug Market Size Market Share by Application (2021-2026)
Table 42. APAC Non-Opioid Pain Drug Market Size by Region (2021-2026) & ($ millions)
Table 43. APAC Non-Opioid Pain Drug Market Size Market Share by Region (2021-2026)
Table 44. APAC Non-Opioid Pain Drug Market Size by Type (2021-2026) & ($ millions)
Table 45. APAC Non-Opioid Pain Drug Market Size by Application (2021-2026) & ($ millions)
Table 46. Europe Non-Opioid Pain Drug Market Size by Country (2021-2026) & ($ millions)
Table 47. Europe Non-Opioid Pain Drug Market Size Market Share by Country (2021-2026)
Table 48. Europe Non-Opioid Pain Drug Market Size by Type (2021-2026) & ($ millions)
Table 49. Europe Non-Opioid Pain Drug Market Size by Application (2021-2026) & ($ millions)
Table 50. Middle East & Africa Non-Opioid Pain Drug Market Size by Region (2021-2026) & ($ millions)
Table 51. Middle East & Africa Non-Opioid Pain Drug Market Size by Type (2021-2026) & ($ millions)
Table 52. Middle East & Africa Non-Opioid Pain Drug Market Size by Application (2021-2026) & ($ millions)
Table 53. Key Market Drivers & Growth Opportunities of Non-Opioid Pain Drug
Table 54. Key Market Challenges & Risks of Non-Opioid Pain Drug
Table 55. Key Industry Trends of Non-Opioid Pain Drug
Table 56. Global Non-Opioid Pain Drug Market Size Forecast by Region (2027-2032) & ($ millions)
Table 57. Global Non-Opioid Pain Drug Market Size Market Share Forecast by Region (2027-2032)
Table 58. Global Non-Opioid Pain Drug Market Size Forecast by Type (2027-2032) & ($ millions)
Table 59. Global Non-Opioid Pain Drug Market Size Forecast by Application (2027-2032) & ($ millions)
Table 60. Vertex Pharmaceuticals Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 61. Vertex Pharmaceuticals Non-Opioid Pain Drug Product Offered
Table 62. Vertex Pharmaceuticals Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 63. Vertex Pharmaceuticals Main Business
Table 64. Vertex Pharmaceuticals Latest Developments
Table 65. Kenvue Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 66. Kenvue Non-Opioid Pain Drug Product Offered
Table 67. Kenvue Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 68. Kenvue Main Business
Table 69. Kenvue Latest Developments
Table 70. Haleon Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 71. Haleon Non-Opioid Pain Drug Product Offered
Table 72. Haleon Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 73. Haleon Main Business
Table 74. Haleon Latest Developments
Table 75. Bayer Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 76. Bayer Non-Opioid Pain Drug Product Offered
Table 77. Bayer Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 78. Bayer Main Business
Table 79. Bayer Latest Developments
Table 80. Pfizer Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 81. Pfizer Non-Opioid Pain Drug Product Offered
Table 82. Pfizer Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 83. Pfizer Main Business
Table 84. Pfizer Latest Developments
Table 85. Pacira BioSciences Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 86. Pacira BioSciences Non-Opioid Pain Drug Product Offered
Table 87. Pacira BioSciences Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 88. Pacira BioSciences Main Business
Table 89. Pacira BioSciences Latest Developments
Table 90. Heron Therapeutics Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 91. Heron Therapeutics Non-Opioid Pain Drug Product Offered
Table 92. Heron Therapeutics Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 93. Heron Therapeutics Main Business
Table 94. Heron Therapeutics Latest Developments
Table 95. Scilex Holding Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 96. Scilex Holding Non-Opioid Pain Drug Product Offered
Table 97. Scilex Holding Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 98. Scilex Holding Main Business
Table 99. Scilex Holding Latest Developments
Table 100. Gr?nenthal Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 101. Gr?nenthal Non-Opioid Pain Drug Product Offered
Table 102. Gr?nenthal Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 103. Gr?nenthal Main Business
Table 104. Gr?nenthal Latest Developments
Table 105. Hisamitsu Pharmaceutical Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 106. Hisamitsu Pharmaceutical Non-Opioid Pain Drug Product Offered
Table 107. Hisamitsu Pharmaceutical Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 108. Hisamitsu Pharmaceutical Main Business
Table 109. Hisamitsu Pharmaceutical Latest Developments
Table 110. Daiichi Sankyo Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 111. Daiichi Sankyo Non-Opioid Pain Drug Product Offered
Table 112. Daiichi Sankyo Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 113. Daiichi Sankyo Main Business
Table 114. Daiichi Sankyo Latest Developments
Table 115. AFT Pharmaceuticals Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 116. AFT Pharmaceuticals Non-Opioid Pain Drug Product Offered
Table 117. AFT Pharmaceuticals Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 118. AFT Pharmaceuticals Main Business
Table 119. AFT Pharmaceuticals Latest Developments
Table 120. Viatris Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 121. Viatris Non-Opioid Pain Drug Product Offered
Table 122. Viatris Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 123. Viatris Main Business
Table 124. Viatris Latest Developments
Table 125. Teva Pharmaceutical Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 126. Teva Pharmaceutical Non-Opioid Pain Drug Product Offered
Table 127. Teva Pharmaceutical Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 128. Teva Pharmaceutical Main Business
Table 129. Teva Pharmaceutical Latest Developments
Table 130. Dr. Reddy's Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 131. Dr. Reddy's Non-Opioid Pain Drug Product Offered
Table 132. Dr. Reddy's Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 133. Dr. Reddy's Main Business
Table 134. Dr. Reddy's Latest Developments
Table 135. Sun Pharmaceutical Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 136. Sun Pharmaceutical Non-Opioid Pain Drug Product Offered
Table 137. Sun Pharmaceutical Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 138. Sun Pharmaceutical Main Business
Table 139. Sun Pharmaceutical Latest Developments
Table 140. Jiangsu Hengrui Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 141. Jiangsu Hengrui Non-Opioid Pain Drug Product Offered
Table 142. Jiangsu Hengrui Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 143. Jiangsu Hengrui Main Business
Table 144. Jiangsu Hengrui Latest Developments
Table 145. Johnson & Johnson Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 146. Johnson & Johnson Non-Opioid Pain Drug Product Offered
Table 147. Johnson & Johnson Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 148. Johnson & Johnson Main Business
Table 149. Johnson & Johnson Latest Developments
Table 150. Hubei Hendi Pharmaceutical Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 151. Hubei Hendi Pharmaceutical Non-Opioid Pain Drug Product Offered
Table 152. Hubei Hendi Pharmaceutical Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 153. Hubei Hendi Pharmaceutical Main Business
Table 154. Hubei Hendi Pharmaceutical Latest Developments
Table 155. CSPC Pharmaceutical Group Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 156. CSPC Pharmaceutical Group Non-Opioid Pain Drug Product Offered
Table 157. CSPC Pharmaceutical Group Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 158. CSPC Pharmaceutical Group Main Business
Table 159. CSPC Pharmaceutical Group Latest Developments
Table 160. Simcere Pharmaceutical Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 161. Simcere Pharmaceutical Non-Opioid Pain Drug Product Offered
Table 162. Simcere Pharmaceutical Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 163. Simcere Pharmaceutical Main Business
Table 164. Simcere Pharmaceutical Latest Developments
Table 165. Qilu Pharmaceutical Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 166. Qilu Pharmaceutical Non-Opioid Pain Drug Product Offered
Table 167. Qilu Pharmaceutical Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 168. Qilu Pharmaceutical Main Business
Table 169. Qilu Pharmaceutical Latest Developments
Table 170. Yichang Humanwell Pharmaceutical Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 171. Yichang Humanwell Pharmaceutical Non-Opioid Pain Drug Product Offered
Table 172. Yichang Humanwell Pharmaceutical Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 173. Yichang Humanwell Pharmaceutical Main Business
Table 174. Yichang Humanwell Pharmaceutical Latest Developments
Table 175. Tongfang Pharma Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 176. Tongfang Pharma Non-Opioid Pain Drug Product Offered
Table 177. Tongfang Pharma Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 178. Tongfang Pharma Main Business
Table 179. Tongfang Pharma Latest Developments
Table 180. Fresenius Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 181. Fresenius Non-Opioid Pain Drug Product Offered
Table 182. Fresenius Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 183. Fresenius Main Business
Table 184. Fresenius Latest Developments
Table 1. Non-Opioid Pain Drug Market Size CAGR by Region (2021 VS 2025 VS 2032) & ($ millions)
Table 2. Non-Opioid Pain Drug Annual Sales CAGR by Country/Region (2021, 2025 & 2032) & ($ millions)
Table 3. Major Players of Acetaminophen/Paracetamol
Table 4. Major Players of Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
Table 5. Major Players of Selective COX-2 Inhibitors
Table 6. Major Players of Sodium Channel Pain Signal Inhibitors
Table 7. Major Players of Local Anesthetic Analgesics
Table 8. Major Players of Other
Table 9. Non-Opioid Pain Drug Market Size CAGR by Type (2021 VS 2025 VS 2032) & ($ millions)
Table 10. Global Non-Opioid Pain Drug Market Size by Type (2021-2026) & ($ millions)
Table 11. Global Non-Opioid Pain Drug Market Size Market Share by Type (2021-2026)
Table 12. Major Players of Single-Agent Drugs
Table 13. Major Players of Combination Drugs
Table 14. Non-Opioid Pain Drug Market Size CAGR by Drug Ingredients (2021 VS 2025 VS 2032) & ($ millions)
Table 15. Global Non-Opioid Pain Drug Market Size by Drug Ingredients (2021-2026) & ($ millions)
Table 16. Global Non-Opioid Pain Drug Market Size Market Share by Drug Ingredients (2021-2026)
Table 17. Major Players of Oral Drugs
Table 18. Major Players of Injectable Drugs
Table 19. Major Players of Topical Drugs
Table 20. Non-Opioid Pain Drug Market Size CAGR by Route of Administration (2021 VS 2025 VS 2032) & ($ millions)
Table 21. Global Non-Opioid Pain Drug Market Size by Route of Administration (2021-2026) & ($ millions)
Table 22. Global Non-Opioid Pain Drug Market Size Market Share by Route of Administration (2021-2026)
Table 23. Non-Opioid Pain Drug Market Size CAGR by Application (2021 VS 2025 VS 2032) & ($ millions)
Table 24. Global Non-Opioid Pain Drug Market Size by Application (2021-2026) & ($ millions)
Table 25. Global Non-Opioid Pain Drug Market Size Market Share by Application (2021-2026)
Table 26. Global Non-Opioid Pain Drug Revenue by Player (2021-2026) & ($ millions)
Table 27. Global Non-Opioid Pain Drug Revenue Market Share by Player (2021-2026)
Table 28. Non-Opioid Pain Drug Key Players Head office and Products Offered
Table 29. Non-Opioid Pain Drug Concentration Ratio (CR3, CR5 and CR10) & (2024-2026)
Table 30. New Products and Potential Entrants
Table 31. Mergers & Acquisitions, Expansion
Table 32. Global Non-Opioid Pain Drug Market Size by Region (2021-2026) & ($ millions)
Table 33. Global Non-Opioid Pain Drug Market Size Market Share by Region (2021-2026)
Table 34. Global Non-Opioid Pain Drug Revenue by Country/Region (2021-2026) & ($ millions)
Table 35. Global Non-Opioid Pain Drug Revenue Market Share by Country/Region (2021-2026)
Table 36. Americas Non-Opioid Pain Drug Market Size by Country (2021-2026) & ($ millions)
Table 37. Americas Non-Opioid Pain Drug Market Size Market Share by Country (2021-2026)
Table 38. Americas Non-Opioid Pain Drug Market Size by Type (2021-2026) & ($ millions)
Table 39. Americas Non-Opioid Pain Drug Market Size Market Share by Type (2021-2026)
Table 40. Americas Non-Opioid Pain Drug Market Size by Application (2021-2026) & ($ millions)
Table 41. Americas Non-Opioid Pain Drug Market Size Market Share by Application (2021-2026)
Table 42. APAC Non-Opioid Pain Drug Market Size by Region (2021-2026) & ($ millions)
Table 43. APAC Non-Opioid Pain Drug Market Size Market Share by Region (2021-2026)
Table 44. APAC Non-Opioid Pain Drug Market Size by Type (2021-2026) & ($ millions)
Table 45. APAC Non-Opioid Pain Drug Market Size by Application (2021-2026) & ($ millions)
Table 46. Europe Non-Opioid Pain Drug Market Size by Country (2021-2026) & ($ millions)
Table 47. Europe Non-Opioid Pain Drug Market Size Market Share by Country (2021-2026)
Table 48. Europe Non-Opioid Pain Drug Market Size by Type (2021-2026) & ($ millions)
Table 49. Europe Non-Opioid Pain Drug Market Size by Application (2021-2026) & ($ millions)
Table 50. Middle East & Africa Non-Opioid Pain Drug Market Size by Region (2021-2026) & ($ millions)
Table 51. Middle East & Africa Non-Opioid Pain Drug Market Size by Type (2021-2026) & ($ millions)
Table 52. Middle East & Africa Non-Opioid Pain Drug Market Size by Application (2021-2026) & ($ millions)
Table 53. Key Market Drivers & Growth Opportunities of Non-Opioid Pain Drug
Table 54. Key Market Challenges & Risks of Non-Opioid Pain Drug
Table 55. Key Industry Trends of Non-Opioid Pain Drug
Table 56. Global Non-Opioid Pain Drug Market Size Forecast by Region (2027-2032) & ($ millions)
Table 57. Global Non-Opioid Pain Drug Market Size Market Share Forecast by Region (2027-2032)
Table 58. Global Non-Opioid Pain Drug Market Size Forecast by Type (2027-2032) & ($ millions)
Table 59. Global Non-Opioid Pain Drug Market Size Forecast by Application (2027-2032) & ($ millions)
Table 60. Vertex Pharmaceuticals Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 61. Vertex Pharmaceuticals Non-Opioid Pain Drug Product Offered
Table 62. Vertex Pharmaceuticals Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 63. Vertex Pharmaceuticals Main Business
Table 64. Vertex Pharmaceuticals Latest Developments
Table 65. Kenvue Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 66. Kenvue Non-Opioid Pain Drug Product Offered
Table 67. Kenvue Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 68. Kenvue Main Business
Table 69. Kenvue Latest Developments
Table 70. Haleon Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 71. Haleon Non-Opioid Pain Drug Product Offered
Table 72. Haleon Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 73. Haleon Main Business
Table 74. Haleon Latest Developments
Table 75. Bayer Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 76. Bayer Non-Opioid Pain Drug Product Offered
Table 77. Bayer Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 78. Bayer Main Business
Table 79. Bayer Latest Developments
Table 80. Pfizer Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 81. Pfizer Non-Opioid Pain Drug Product Offered
Table 82. Pfizer Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 83. Pfizer Main Business
Table 84. Pfizer Latest Developments
Table 85. Pacira BioSciences Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 86. Pacira BioSciences Non-Opioid Pain Drug Product Offered
Table 87. Pacira BioSciences Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 88. Pacira BioSciences Main Business
Table 89. Pacira BioSciences Latest Developments
Table 90. Heron Therapeutics Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 91. Heron Therapeutics Non-Opioid Pain Drug Product Offered
Table 92. Heron Therapeutics Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 93. Heron Therapeutics Main Business
Table 94. Heron Therapeutics Latest Developments
Table 95. Scilex Holding Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 96. Scilex Holding Non-Opioid Pain Drug Product Offered
Table 97. Scilex Holding Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 98. Scilex Holding Main Business
Table 99. Scilex Holding Latest Developments
Table 100. Gr?nenthal Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 101. Gr?nenthal Non-Opioid Pain Drug Product Offered
Table 102. Gr?nenthal Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 103. Gr?nenthal Main Business
Table 104. Gr?nenthal Latest Developments
Table 105. Hisamitsu Pharmaceutical Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 106. Hisamitsu Pharmaceutical Non-Opioid Pain Drug Product Offered
Table 107. Hisamitsu Pharmaceutical Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 108. Hisamitsu Pharmaceutical Main Business
Table 109. Hisamitsu Pharmaceutical Latest Developments
Table 110. Daiichi Sankyo Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 111. Daiichi Sankyo Non-Opioid Pain Drug Product Offered
Table 112. Daiichi Sankyo Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 113. Daiichi Sankyo Main Business
Table 114. Daiichi Sankyo Latest Developments
Table 115. AFT Pharmaceuticals Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 116. AFT Pharmaceuticals Non-Opioid Pain Drug Product Offered
Table 117. AFT Pharmaceuticals Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 118. AFT Pharmaceuticals Main Business
Table 119. AFT Pharmaceuticals Latest Developments
Table 120. Viatris Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 121. Viatris Non-Opioid Pain Drug Product Offered
Table 122. Viatris Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 123. Viatris Main Business
Table 124. Viatris Latest Developments
Table 125. Teva Pharmaceutical Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 126. Teva Pharmaceutical Non-Opioid Pain Drug Product Offered
Table 127. Teva Pharmaceutical Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 128. Teva Pharmaceutical Main Business
Table 129. Teva Pharmaceutical Latest Developments
Table 130. Dr. Reddy's Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 131. Dr. Reddy's Non-Opioid Pain Drug Product Offered
Table 132. Dr. Reddy's Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 133. Dr. Reddy's Main Business
Table 134. Dr. Reddy's Latest Developments
Table 135. Sun Pharmaceutical Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 136. Sun Pharmaceutical Non-Opioid Pain Drug Product Offered
Table 137. Sun Pharmaceutical Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 138. Sun Pharmaceutical Main Business
Table 139. Sun Pharmaceutical Latest Developments
Table 140. Jiangsu Hengrui Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 141. Jiangsu Hengrui Non-Opioid Pain Drug Product Offered
Table 142. Jiangsu Hengrui Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 143. Jiangsu Hengrui Main Business
Table 144. Jiangsu Hengrui Latest Developments
Table 145. Johnson & Johnson Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 146. Johnson & Johnson Non-Opioid Pain Drug Product Offered
Table 147. Johnson & Johnson Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 148. Johnson & Johnson Main Business
Table 149. Johnson & Johnson Latest Developments
Table 150. Hubei Hendi Pharmaceutical Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 151. Hubei Hendi Pharmaceutical Non-Opioid Pain Drug Product Offered
Table 152. Hubei Hendi Pharmaceutical Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 153. Hubei Hendi Pharmaceutical Main Business
Table 154. Hubei Hendi Pharmaceutical Latest Developments
Table 155. CSPC Pharmaceutical Group Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 156. CSPC Pharmaceutical Group Non-Opioid Pain Drug Product Offered
Table 157. CSPC Pharmaceutical Group Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 158. CSPC Pharmaceutical Group Main Business
Table 159. CSPC Pharmaceutical Group Latest Developments
Table 160. Simcere Pharmaceutical Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 161. Simcere Pharmaceutical Non-Opioid Pain Drug Product Offered
Table 162. Simcere Pharmaceutical Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 163. Simcere Pharmaceutical Main Business
Table 164. Simcere Pharmaceutical Latest Developments
Table 165. Qilu Pharmaceutical Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 166. Qilu Pharmaceutical Non-Opioid Pain Drug Product Offered
Table 167. Qilu Pharmaceutical Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 168. Qilu Pharmaceutical Main Business
Table 169. Qilu Pharmaceutical Latest Developments
Table 170. Yichang Humanwell Pharmaceutical Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 171. Yichang Humanwell Pharmaceutical Non-Opioid Pain Drug Product Offered
Table 172. Yichang Humanwell Pharmaceutical Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 173. Yichang Humanwell Pharmaceutical Main Business
Table 174. Yichang Humanwell Pharmaceutical Latest Developments
Table 175. Tongfang Pharma Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 176. Tongfang Pharma Non-Opioid Pain Drug Product Offered
Table 177. Tongfang Pharma Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 178. Tongfang Pharma Main Business
Table 179. Tongfang Pharma Latest Developments
Table 180. Fresenius Details, Company Type, Non-Opioid Pain Drug Area Served and Its Competitors
Table 181. Fresenius Non-Opioid Pain Drug Product Offered
Table 182. Fresenius Non-Opioid Pain Drug Revenue ($ million), Gross Margin and Market Share (2021-2026)
Table 183. Fresenius Main Business
Table 184. Fresenius Latest Developments
LIST OF FIGURES
Figure 1. Non-Opioid Pain Drug Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Non-Opioid Pain Drug Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Non-Opioid Pain Drug Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Non-Opioid Pain Drug Sales Market Share by Country/Region (2025)
Figure 8. Non-Opioid Pain Drug Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Non-Opioid Pain Drug Market Size Market Share by Type in 2025
Figure 10. Global Non-Opioid Pain Drug Market Size Market Share by Drug Ingredients in 2025
Figure 11. Global Non-Opioid Pain Drug Market Size Market Share by Route of Administration in 2025
Figure 12. Non-Opioid Pain Drug in Postoperative Pain
Figure 13. Global Non-Opioid Pain Drug Market: Postoperative Pain (2021-2026) & ($ millions)
Figure 14. Non-Opioid Pain Drug in Musculoskeletal Pain
Figure 15. Global Non-Opioid Pain Drug Market: Musculoskeletal Pain (2021-2026) & ($ millions)
Figure 16. Non-Opioid Pain Drug in Arthritis Pain
Figure 17. Global Non-Opioid Pain Drug Market: Arthritis Pain (2021-2026) & ($ millions)
Figure 18. Non-Opioid Pain Drug in Neuropathic Pain
Figure 19. Global Non-Opioid Pain Drug Market: Neuropathic Pain (2021-2026) & ($ millions)
Figure 20. Non-Opioid Pain Drug in Headache and Migraine
Figure 21. Global Non-Opioid Pain Drug Market: Headache and Migraine (2021-2026) & ($ millions)
Figure 22. Non-Opioid Pain Drug in Other
Figure 23. Global Non-Opioid Pain Drug Market: Other (2021-2026) & ($ millions)
Figure 24. Global Non-Opioid Pain Drug Market Size Market Share by Application in 2025
Figure 25. Global Non-Opioid Pain Drug Revenue Market Share by Player in 2025
Figure 26. Global Non-Opioid Pain Drug Market Size Market Share by Region (2021-2026)
Figure 27. Americas Non-Opioid Pain Drug Market Size 2021-2026 ($ millions)
Figure 28. APAC Non-Opioid Pain Drug Market Size 2021-2026 ($ millions)
Figure 29. Europe Non-Opioid Pain Drug Market Size 2021-2026 ($ millions)
Figure 30. Middle East & Africa Non-Opioid Pain Drug Market Size 2021-2026 ($ millions)
Figure 31. Americas Non-Opioid Pain Drug Value Market Share by Country in 2025
Figure 32. United States Non-Opioid Pain Drug Market Size Growth 2021-2026 ($ millions)
Figure 33. Canada Non-Opioid Pain Drug Market Size Growth 2021-2026 ($ millions)
Figure 34. Mexico Non-Opioid Pain Drug Market Size Growth 2021-2026 ($ millions)
Figure 35. Brazil Non-Opioid Pain Drug Market Size Growth 2021-2026 ($ millions)
Figure 36. APAC Non-Opioid Pain Drug Market Size Market Share by Region in 2025
Figure 37. APAC Non-Opioid Pain Drug Market Size Market Share by Type (2021-2026)
Figure 38. APAC Non-Opioid Pain Drug Market Size Market Share by Application (2021-2026)
Figure 39. China Non-Opioid Pain Drug Market Size Growth 2021-2026 ($ millions)
Figure 40. Japan Non-Opioid Pain Drug Market Size Growth 2021-2026 ($ millions)
Figure 41. South Korea Non-Opioid Pain Drug Market Size Growth 2021-2026 ($ millions)
Figure 42. Southeast Asia Non-Opioid Pain Drug Market Size Growth 2021-2026 ($ millions)
Figure 43. India Non-Opioid Pain Drug Market Size Growth 2021-2026 ($ millions)
Figure 44. Australia Non-Opioid Pain Drug Market Size Growth 2021-2026 ($ millions)
Figure 45. Europe Non-Opioid Pain Drug Market Size Market Share by Country in 2025
Figure 46. Europe Non-Opioid Pain Drug Market Size Market Share by Type (2021-2026)
Figure 47. Europe Non-Opioid Pain Drug Market Size Market Share by Application (2021-2026)
Figure 48. Germany Non-Opioid Pain Drug Market Size Growth 2021-2026 ($ millions)
Figure 49. France Non-Opioid Pain Drug Market Size Growth 2021-2026 ($ millions)
Figure 50. UK Non-Opioid Pain Drug Market Size Growth 2021-2026 ($ millions)
Figure 51. Italy Non-Opioid Pain Drug Market Size Growth 2021-2026 ($ millions)
Figure 52. Russia Non-Opioid Pain Drug Market Size Growth 2021-2026 ($ millions)
Figure 53. Middle East & Africa Non-Opioid Pain Drug Market Size Market Share by Region (2021-2026)
Figure 54. Middle East & Africa Non-Opioid Pain Drug Market Size Market Share by Type (2021-2026)
Figure 55. Middle East & Africa Non-Opioid Pain Drug Market Size Market Share by Application (2021-2026)
Figure 56. Egypt Non-Opioid Pain Drug Market Size Growth 2021-2026 ($ millions)
Figure 57. South Africa Non-Opioid Pain Drug Market Size Growth 2021-2026 ($ millions)
Figure 58. Israel Non-Opioid Pain Drug Market Size Growth 2021-2026 ($ millions)
Figure 59. Turkey Non-Opioid Pain Drug Market Size Growth 2021-2026 ($ millions)
Figure 60. GCC Countries Non-Opioid Pain Drug Market Size Growth 2021-2026 ($ millions)
Figure 61. Americas Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 62. APAC Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 63. Europe Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 64. Middle East & Africa Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 65. United States Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 66. Canada Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 67. Mexico Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 68. Brazil Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 69. China Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 70. Japan Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 71. Korea Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 72. Southeast Asia Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 73. India Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 74. Australia Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 75. Germany Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 76. France Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 77. UK Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 78. Italy Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 79. Russia Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 80. Egypt Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 81. South Africa Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 82. Israel Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 83. Turkey Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 84. Global Non-Opioid Pain Drug Market Size Market Share Forecast by Type (2027-2032)
Figure 85. Global Non-Opioid Pain Drug Market Size Market Share Forecast by Application (2027-2032)
Figure 86. GCC Countries Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 1. Non-Opioid Pain Drug Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Non-Opioid Pain Drug Market Size Growth Rate (2021-2032) ($ millions)
Figure 6. Non-Opioid Pain Drug Sales by Geographic Region (2021, 2025 & 2032) & ($ millions)
Figure 7. Non-Opioid Pain Drug Sales Market Share by Country/Region (2025)
Figure 8. Non-Opioid Pain Drug Sales Market Share by Country/Region (2021, 2025 & 2032)
Figure 9. Global Non-Opioid Pain Drug Market Size Market Share by Type in 2025
Figure 10. Global Non-Opioid Pain Drug Market Size Market Share by Drug Ingredients in 2025
Figure 11. Global Non-Opioid Pain Drug Market Size Market Share by Route of Administration in 2025
Figure 12. Non-Opioid Pain Drug in Postoperative Pain
Figure 13. Global Non-Opioid Pain Drug Market: Postoperative Pain (2021-2026) & ($ millions)
Figure 14. Non-Opioid Pain Drug in Musculoskeletal Pain
Figure 15. Global Non-Opioid Pain Drug Market: Musculoskeletal Pain (2021-2026) & ($ millions)
Figure 16. Non-Opioid Pain Drug in Arthritis Pain
Figure 17. Global Non-Opioid Pain Drug Market: Arthritis Pain (2021-2026) & ($ millions)
Figure 18. Non-Opioid Pain Drug in Neuropathic Pain
Figure 19. Global Non-Opioid Pain Drug Market: Neuropathic Pain (2021-2026) & ($ millions)
Figure 20. Non-Opioid Pain Drug in Headache and Migraine
Figure 21. Global Non-Opioid Pain Drug Market: Headache and Migraine (2021-2026) & ($ millions)
Figure 22. Non-Opioid Pain Drug in Other
Figure 23. Global Non-Opioid Pain Drug Market: Other (2021-2026) & ($ millions)
Figure 24. Global Non-Opioid Pain Drug Market Size Market Share by Application in 2025
Figure 25. Global Non-Opioid Pain Drug Revenue Market Share by Player in 2025
Figure 26. Global Non-Opioid Pain Drug Market Size Market Share by Region (2021-2026)
Figure 27. Americas Non-Opioid Pain Drug Market Size 2021-2026 ($ millions)
Figure 28. APAC Non-Opioid Pain Drug Market Size 2021-2026 ($ millions)
Figure 29. Europe Non-Opioid Pain Drug Market Size 2021-2026 ($ millions)
Figure 30. Middle East & Africa Non-Opioid Pain Drug Market Size 2021-2026 ($ millions)
Figure 31. Americas Non-Opioid Pain Drug Value Market Share by Country in 2025
Figure 32. United States Non-Opioid Pain Drug Market Size Growth 2021-2026 ($ millions)
Figure 33. Canada Non-Opioid Pain Drug Market Size Growth 2021-2026 ($ millions)
Figure 34. Mexico Non-Opioid Pain Drug Market Size Growth 2021-2026 ($ millions)
Figure 35. Brazil Non-Opioid Pain Drug Market Size Growth 2021-2026 ($ millions)
Figure 36. APAC Non-Opioid Pain Drug Market Size Market Share by Region in 2025
Figure 37. APAC Non-Opioid Pain Drug Market Size Market Share by Type (2021-2026)
Figure 38. APAC Non-Opioid Pain Drug Market Size Market Share by Application (2021-2026)
Figure 39. China Non-Opioid Pain Drug Market Size Growth 2021-2026 ($ millions)
Figure 40. Japan Non-Opioid Pain Drug Market Size Growth 2021-2026 ($ millions)
Figure 41. South Korea Non-Opioid Pain Drug Market Size Growth 2021-2026 ($ millions)
Figure 42. Southeast Asia Non-Opioid Pain Drug Market Size Growth 2021-2026 ($ millions)
Figure 43. India Non-Opioid Pain Drug Market Size Growth 2021-2026 ($ millions)
Figure 44. Australia Non-Opioid Pain Drug Market Size Growth 2021-2026 ($ millions)
Figure 45. Europe Non-Opioid Pain Drug Market Size Market Share by Country in 2025
Figure 46. Europe Non-Opioid Pain Drug Market Size Market Share by Type (2021-2026)
Figure 47. Europe Non-Opioid Pain Drug Market Size Market Share by Application (2021-2026)
Figure 48. Germany Non-Opioid Pain Drug Market Size Growth 2021-2026 ($ millions)
Figure 49. France Non-Opioid Pain Drug Market Size Growth 2021-2026 ($ millions)
Figure 50. UK Non-Opioid Pain Drug Market Size Growth 2021-2026 ($ millions)
Figure 51. Italy Non-Opioid Pain Drug Market Size Growth 2021-2026 ($ millions)
Figure 52. Russia Non-Opioid Pain Drug Market Size Growth 2021-2026 ($ millions)
Figure 53. Middle East & Africa Non-Opioid Pain Drug Market Size Market Share by Region (2021-2026)
Figure 54. Middle East & Africa Non-Opioid Pain Drug Market Size Market Share by Type (2021-2026)
Figure 55. Middle East & Africa Non-Opioid Pain Drug Market Size Market Share by Application (2021-2026)
Figure 56. Egypt Non-Opioid Pain Drug Market Size Growth 2021-2026 ($ millions)
Figure 57. South Africa Non-Opioid Pain Drug Market Size Growth 2021-2026 ($ millions)
Figure 58. Israel Non-Opioid Pain Drug Market Size Growth 2021-2026 ($ millions)
Figure 59. Turkey Non-Opioid Pain Drug Market Size Growth 2021-2026 ($ millions)
Figure 60. GCC Countries Non-Opioid Pain Drug Market Size Growth 2021-2026 ($ millions)
Figure 61. Americas Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 62. APAC Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 63. Europe Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 64. Middle East & Africa Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 65. United States Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 66. Canada Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 67. Mexico Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 68. Brazil Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 69. China Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 70. Japan Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 71. Korea Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 72. Southeast Asia Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 73. India Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 74. Australia Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 75. Germany Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 76. France Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 77. UK Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 78. Italy Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 79. Russia Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 80. Egypt Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 81. South Africa Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 82. Israel Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 83. Turkey Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
Figure 84. Global Non-Opioid Pain Drug Market Size Market Share Forecast by Type (2027-2032)
Figure 85. Global Non-Opioid Pain Drug Market Size Market Share Forecast by Application (2027-2032)
Figure 86. GCC Countries Non-Opioid Pain Drug Market Size 2027-2032 ($ millions)
